Annovis Bio (NYSE: ANVS) reported first-quarter 2026 business and financial results, highlighting continued advancement of its clinical-stage neurodegenerative disease programs. The company announced that its pivotal Phase 3 Alzheimer’s disease trial has achieved 85% enrollment, with enrollment closed to new participants after reaching sufficient screening levels to meet enrollment goals. This milestone brings Annovis closer to potential regulatory submission for buntanetap, its lead drug candidate targeting multiple neurotoxic proteins involved in Alzheimer’s and Parkinson’s diseases.
The company also reported progress in its Parkinson’s disease open-label extension study, which has reached 40% enrollment. Alongside these clinical achievements, Annovis is pursuing new biomarker initiatives and AI-powered digital monitoring to enhance data collection and analysis. These efforts are part of a broader strategy to address the underlying causes of neurodegeneration and improve cognitive and motor functions in patients.
Buntanetap (formerly posiphen) is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By targeting these proteins, Annovis aims to halt disease progression in Alzheimer’s and Parkinson’s diseases. The company is headquartered in Malvern, Pennsylvania, and is focused on developing treatments for neurodegenerative diseases.
For more details on the press release, visit https://ibn.fm/M77X4. Additional information about Annovis Bio is available at www.annovisbio.com, and the latest news on ANVS can be found in the company’s newsroom at https://ibn.fm/ANVS.
The announcement underscores Annovis’s progress toward addressing significant unmet needs in neurodegenerative diseases. With high enrollment in its Phase 3 Alzheimer’s trial and advancing Parkinson’s studies, the company is positioning buntanetap as a potential disease-modifying therapy. The integration of AI and biomarkers could further strengthen its clinical data package, supporting future regulatory submissions.